Invitrogen Launches In Vivo RNAi Delivery Reagent

  
    
  
  
    
      Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life 
      science technologies for research, production and diagnostics, today 
      announced the introduction of its Invivofectamine™ delivery reagent 
      which enables short interference ribonucleic acid (siRNA) experiments in 
      vivo.
    
    
      The study of RNA interference (RNAi) has revolutionized biology by 
      allowing researchers to directly observe the effects of the loss of 
      function of specific genes in mammalian systems. Using proprietary 
      technology, the Invivofectamine™ delivery reagent allows researchers to 
      directly study the effects of siRNA inside a living organism for a 
      variety of applications, including the drug discovery process.
    
    
      “The Invivofectamine™ reagent is a major breakthrough for the 
      development of RNAi applications in animals that could lead to the rapid 
      discovery of new therapeutic solutions for diseases such as cancer and 
      metabolic diseases,” said Charles Piazza, Vice President and General 
      Manager of Invitrogen’s Molecular Biology. “Invivofectamine™ reagent 
      gives customers the ability to perform in vivo RNAi experiments 
      that have so far been difficult to perform due to the lack of an 
      effective and easy-to-use delivery reagent.”
    
    
      As opposed to current offerings on the market, Invivofectamine™ delivery 
      reagent can be injected in small volumes and without high pressure, 
      minimizing the potential of inconsistent results. It also provides extra 
      stability to siRNA so the siRNA will arrive intact and ready to perform 
      the selected knockdown. The reagent is non-viral and has minimal 
      toxicity. Overall, these characteristics will enable researchers to more 
      effectively optimize their siRNA experiments in vivo.
    
    
      For more information, visit www.invitrogen.com/invivornai.
    
    
      About Invitrogen
    
    
      Invitrogen Corporation (NASDAQ:IVGN) provides products and services that 
      support academic and government research institutions and pharmaceutical 
      and biotech companies worldwide in their efforts to improve the human 
      condition. The company provides essential life science technologies for 
      disease research, drug discovery, and commercial bioproduction. 
      Invitrogen's own research and development efforts are focused on 
      breakthrough innovation in all major areas of biological discovery 
      including functional genomics, proteomics, stem cells, cell therapy and 
      cell biology -- placing Invitrogen's products in nearly every major 
      laboratory in the world. Founded in 1987, Invitrogen is headquartered in 
      Carlsbad, California, and conducts business in more than 70 countries 
      around the world. The company employs approximately 4,700 scientists and 
      other professionals and had revenues of approximately $1.3 billion in 
      2007. For more information, visit www.invitrogen.com.
    
    
      Safe Harbor Statement
    
    
      Certain statements contained in this press release are considered 
      "forward-looking statements" within the meaning of the Private 
      Securities Litigation Reform Act of 1995, and it is Invitrogen's intent 
      that such statements be protected by the safe harbor created thereby. 
      Forward looking statements include, but are not limited to; 1) the 
      characteristics of Invivofectamine™ delivery reagent listed above will 
      enable researchers to more effectively optimize their siRNA experiments in 
      vivo. Potential risks and uncertainties include, but are not limited 
      to; a) Invivofectamine™ delivery reagent may or may not allow 
      researchers to study the effects of siRNA in vivo or inside a 
      living organism, nor lead to rapid discovery of therapeutic solutions; 
      b) Invivofectamine™ may or may not provide extra stability to siRNA so 
      the siRNA will arrive intact and ready to perform the selected 
      knockdown; and the risks that the market will not accept the companies’ 
      products and services, or that the companies will be unsuccessful in 
      their efforts to develop new products and services, as well as other 
      risks and uncertainties detailed from time to time in Invitrogen's 
      Securities and Exchange Commission filings.